Navigation Links
Insmed CEO Resigns Due to Health Concerns
Date:6/15/2009

l trial data may take longer than anticipated, competing products may be more successful, the biopharmaceutical industry may experience negative market trends, our continuing efforts to grow the business and develop IPLEX(TM) may be unsuccessful, the actual market for MMD may not actually match up with our external assessment, we may lack financial resources to complete development of product candidates and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2008. Readers are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release. We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

    Investor Relations Contact:
    Brian Ritchie - FD
    212-850-5683
    brian.ritchie@fd.com

    Media Relations Contact:
    Irma Gomez-Dib - FD
    212-850-5761
    irma.gomez-dib@fd.com


'/>"/>
SOURCE Insmed Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Insmed Announces First Quarter 2009 Financial Results
2. Insmed Regains NASDAQ Compliance
3. Insmed to Host First Quarter 2009 Conference Call
4. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
5. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
6. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
7. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
8. Insmed Sells Follow-on Biologics Platform to Merck & Co., Inc. for Gross Proceeds of $130 Million
9. Insmed to Present at Sanford C. Bernstein Biosimilars Long View Conference
10. Insmed Announces Financial Results for Third Quarter and Nine-Months Ended September 30, 2008
11. NASDAQs Temporary Suspension of Minimum Bid Closing Price Rules Extends Insmeds Compliance Date to March 20, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Delpor, ... today announced that the United States Patent and Trademark ... Company’s NANOPOR™ technology. US Pat. No. ... Delpor’s microfabricated drug delivery device for the ... proprietary NANOPOR™ technology for the sustained (zero-order) release of ...
(Date:4/22/2015)... , April 22, 2015 /PRNewswire/ - BioAmber Inc. (NYSE and EURONEXT Paris:BIOA) today ... first quarter 2015 on Thursday, May 7, 2015 after ... a webcast and conference call for 4.30 pm ET ... Live audio of the conference call will be ... investors, members of the news media and the general ...
(Date:4/22/2015)... Calif. , April 22, 2015 ... and analytics, announced today that it has opened ... its continued growth and expansion.  The common stock ... Act, Section 506(c), a law intended to encourage ... regulations.  Prior to 506(c), small businesses largely relied ...
(Date:4/22/2015)... 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... announce that Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... to initiate a Phase 1 pharmacokinetic and biomarker ... Biohaven plans to initiate the trial no later ... in the Phase 1 study, Biohaven will move ...
Breaking Biology Technology:Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3BioAmber Announces Webcast of Fiscal First Quarter 2015 Financial Results 2Steep Hill Launches $5M Limited Stock Offering 2Steep Hill Launches $5M Limited Stock Offering 3Portage's Biohaven to begin Phase 1 study in 3Q2015 and readying for Phase 3 study start by 1Q2016 2Portage's Biohaven to begin Phase 1 study in 3Q2015 and readying for Phase 3 study start by 1Q2016 3
... , , , , ... Inc.,(Nasdaq: SSRX ), a leading biotechnology company focused ... today announced that it has submitted its application for ... Drug,Administration ("SFDA") for Feraheme (ferumoxytol) Injection for intravenous,use. Feraheme ...
... , , ... enrollment of patients with acute ischemic stroke into its,Phase III ... at the Wolfson Medical Center, Israel. The MACSI trial involves,numerous ... Korea and Brazil. DP-b99 is D-Pharm,s most advanced product developed,for ...
... WASHINGTON, Dec. 29 The National Fragile X Foundation applauds ... Fragile X Syndrome for the first time ever within a ... U.S. Department of Defense. , The new law, ... through the FY 2010 Department of Defense Appropriations Act for ...
Cached Biology Technology:3SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 23SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 33SBio Inc. Applies for SFDA Registrational Trial for Feraheme(TM) 4D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 2D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI 3Defense Department to Support Fragile X Research 2
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... , April 1, 2015   Medisafe ™, ... million users across iOS and Android ... begun integrating biofeedback into the platform to allow patients ... outcomes. For the first time, patients will be able ... a dose impacts important biometrics, such as glucose levels ...
(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... have discovered how two closely related proteins guide projections ... repelling these axons as they navigate the most miniscule ... remarkably precise connections. The discovery, reported April 28 ... belonging to the "semaphorin" family of guidance cues are ...
... As part of the Genome Canada Large-Scale Applied Research ... million to 16 projects across the country, the researchers ... function with the aim of identifying genes or proteins ... to target cancers and other diseases. The first ...
... by a parasitic fungus dramatically changes the behavior of tropical ... to become zombie-like and to die at a spot that ... team studied ants living high up in the rainforest canopy ... in the BioMed Central open-access journal BMC Ecology ...
Cached Biology News:Johns Hopkins scientists reveal nerve cells' navigation system 2Johns Hopkins scientists reveal nerve cells' navigation system 3OGI genomics researchers awarded $23 million 2OGI genomics researchers awarded $23 million 3Zombie ants have fungus on the brain, new research reveals 2